𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism

✍ Scribed by R. Klintenberg; P. Svenningsson; L. Gunne; P. E. Andrén

Publisher
Springer
Year
2002
Tongue
English
Weight
419 KB
Volume
109
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stimulation of cannabinoid receptors red
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease
✍ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB 👁 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

Topiramate reduces levodopa-induced dysk
Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease
✍ Monty A. Silverdale; S.L. Nicholson; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

## Abstract Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic actio

Fipamezole (JP-1730) is a potent α2 adre
Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
✍ Juha-Matti Savola; Michael Hill; Mia Engstrom; Hannele Merivuori; Siegfried Wurs 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Previous studies in the MPTP-lesioned primate model of Parkinson's disease have demonstrated that alpha(2) adrenergic receptor antagonists such as idazoxan, rauwolscine, and yohimbine can alleviate L-dopa-induced dyskinesia and, in the case of idazoxan, enhance the duration of anti-parkinsonian acti

Genotype and smoking history affect risk
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease
✍ Judith A. Strong; Arif Dalvi; Fredy J. Revilla; Alok Sahay; Frederick J. Samaha; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this variation may be partially genetic in origin. We determined whether particular dopamine and opioid receptor polymorphisms were associated with risk of earlier onset of dyskinesia side effects during levod

Role of serotonin neurons in the inducti
Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease
✍ Manolo Carta; Thomas Carlsson; Ana Muñoz; Deniz Kirik; Anders Björklund 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract Recent studies in animal models of Parkinson's disease (PD) have provided evidence that dopamine released from spared serotonin afferents can act as a trigger of dyskinetic movements induced by repetitive, low doses of levodopa. Serotonin neurons have the capacity to store and release d